checkAd

     488  0 Kommentare Breadth of data at ECTRIMS underpins Novartis' relentless commitment to decoding the science of multiple sclerosis (MS) and decreasing the patient burden - Seite 4

    About Novartis
    Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.

    Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis
    For Novartis multimedia content, please visit www.novartis.com/news/media-library
    For questions about the site or required registration, please contact media.relations@novartis.com

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Novartis AG!
    Long
    88,98€
    Basispreis
    0,67
    Ask
    × 14,78
    Hebel
    Short
    99,94€
    Basispreis
    0,71
    Ask
    × 13,97
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    References
    [1] An Integral Measure of Serial Neurofilament Light Chain Assessments in Blood is a Predictor of Long-Term Disability Progression in Relapsing-Remitting Multiple Sclerosis. J. Kuhle et. al.
    [2] Neurofilament Light Levels in the Blood of Patients with Secondary Progressive MS are higher than in Primary Progressive MS and may Predict Brain Atrophy in both MS Subtypes. J. Kuhle, et. al.
    [3] Neurofilament Light Chain is a Useful Biomarker in Paediatric Multiple Sclerosis. M. C. Reinert, et. al.
    [4] Longer-Term Safety with Siponimod Treatment in Multiple Sclerosis: Pooled Analysis of Data from the BOLD and EXPAND Trials and their Extensions, L. Kappos, et. al

    # # #

    Novartis Media Relations
    Central media line: +41 61 324 2200
    E-mail: media.relations@novartis.com

    Eric Althoff
    Novartis Global Media Relations
    +41 61 324 7999 (direct)
    +41 79 593 4202 (mobile)
    eric.althoff@novartis.com
    Angela Fiorin
    Novartis Global Pharma Communications
    +41 61 324 8631 (direct)
    +41 79 752 6955 (mobile)
    angela.fiorin@novartis.com

    Lesen Sie auch

    Novartis Investor Relations
    Central investor relations line: +41 61 324 7944
    E-mail: investor.relations@novartis.com

    Central   North America  
    Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448
    Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417
    Thomas Hungerbuehler +41 61 324 8425    
    Isabella Zinck +41 61 324 7188    
    Seite 4 von 5


    Diskutieren Sie über die enthaltenen Werte


    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    Breadth of data at ECTRIMS underpins Novartis' relentless commitment to decoding the science of multiple sclerosis (MS) and decreasing the patient burden - Seite 4 Novartis International AG / Breadth of data at ECTRIMS underpins Novartis' relentless commitment to decoding the science of multiple sclerosis (MS) and decreasing the patient burden . Processed and transmitted by West Corporation. The issuer is …

    Schreibe Deinen Kommentar

    Disclaimer